Yes, you can get pregnant if you have breast cancer, both during active treatment in some cases and after completing therapy. But the timing, safety, and fertility outlook depend heavily on your age, the type of breast cancer, and which treatments you receive. Some treatments carry a real risk of permanent infertility, while others leave fertility largely intact. For women who do conceive after breast cancer, pregnancy outcomes are generally comparable to those of women without a cancer history.
How Treatment Affects Your Fertility
Chemotherapy poses the biggest threat to future fertility, and age is the single strongest predictor of whether your ovaries will recover. Among women under 40 who receive a common regimen of doxorubicin plus cyclophosphamide (often called AC), fewer than 20% experience permanent ovarian failure. For women over 40 on the same regimen, that number jumps to 20% to 80%.
Even when periods return after chemo, that doesn’t guarantee normal fertility. Among women whose menstrual cycles resumed, 5% of those diagnosed at age 30 remained infertile, compared to 32% diagnosed at 35 and 80% diagnosed at 40. The specific drugs matter too. Adding a taxane to AC resulted in the highest rate of absent periods 12 months after treatment (70%), while other combinations came in lower.
Hormone therapy creates a different kind of barrier. Tamoxifen, commonly prescribed for 5 to 10 years in hormone receptor-positive breast cancer, can cause birth defects and must be stopped before attempting pregnancy. Targeted therapies like trastuzumab (used for HER2-positive cancers) are associated with a dangerous loss of amniotic fluid that can cause fetal lung problems or even fetal death, so contraception is recommended during treatment and for up to 7 months after the last dose.
Preserving Your Options Before Treatment
If pregnancy is something you want in the future, the most reliable step is freezing eggs or embryos before starting chemotherapy. The process takes about 10 to 12 days of ovarian stimulation, with the goal of retrieving 10 to 15 eggs. This timeline is short enough that it typically does not delay the start of chemotherapy, even for women beginning treatment before surgery.
The pregnancy rates from frozen eggs and embryos in cancer survivors match those of women who freeze for non-medical reasons. In one study of 80 cancer patients who had their eggs frozen, the live birth rate per transfer was 31%, and the cumulative live birth rate per patient reached about 35% when surplus embryos were included. These numbers are statistically indistinguishable from those of women undergoing fertility treatment for other reasons.
A second, less reliable option is a medication that temporarily suppresses the ovaries during chemotherapy. Two large clinical trials showed this approach reduced rates of permanent ovarian damage and led to higher pregnancy rates compared to chemotherapy alone. However, the degree of protection varies from person to person and can’t be predicted in advance. Medical guidelines recommend this approach only when egg or embryo freezing isn’t feasible.
How Long to Wait After Treatment
The recommended waiting period depends on your cancer subtype and the treatments you received. After chemotherapy, the general recommendation is to wait at least 12 months before trying to conceive. For hormone receptor-positive cancers, the timeline is longer because of the years-long course of hormone therapy. For triple-negative breast cancer, doctors often advise waiting 2 to 3 years after completing treatment, since the highest risk of recurrence falls within that window.
If you’re stopping tamoxifen to conceive, a three-month washout period is generally recommended, though the drug clears the body much faster (its half-life is about 7 days, meaning it’s essentially gone within 35 days). For newer immunotherapy drugs, contraception should continue for 4 to 5 months after the last dose, depending on the specific medication.
Pausing Hormone Therapy to Conceive
One of the biggest questions for women with hormone receptor-positive breast cancer has been whether it’s safe to interrupt years of hormone therapy to have a baby. A landmark trial published in the New England Journal of Medicine provided a clear answer: women who paused their endocrine therapy for up to two years to try to conceive did not face a higher short-term risk of recurrence.
At a median follow-up of 41 months, the three-year rate of breast cancer events was 8.9% in the group that paused treatment, compared to 9.2% in a matched group that did not interrupt therapy. The difference was not statistically meaningful. Most of the women in the study became pregnant within two years of stopping treatment, and all participants resumed hormone therapy afterward to complete their full 5- to 10-year course.
What If You’re Diagnosed While Pregnant
Breast cancer discovered during pregnancy is uncommon but manageable. Surgery is the primary treatment and can be performed during any trimester. If the diagnosis comes early in pregnancy, a mastectomy is typically preferred because radiation therapy poses risks to the fetus. If the cancer is found later in pregnancy, breast-conserving surgery followed by radiation after delivery is an option.
Chemotherapy is generally considered safe in the second and third trimesters. Certain standard regimens have been used during this window with most pregnancies resulting in live births and low rates of complications for the newborn. First-trimester chemotherapy and radiation therapy at any point during pregnancy are avoided due to the risk of birth defects during early fetal development.
BRCA Carriers Face Additional Considerations
Women who carry BRCA1 or BRCA2 mutations face a more complex fertility picture. They may have lower ovarian reserves to begin with and appear to be at greater risk of chemotherapy-induced ovarian damage compared to non-carriers of the same age. Fertility preservation before treatment is especially important for these women, particularly if they’re interested in genetic testing of embryos to avoid passing on the mutation.
A large international study found an important split between the two genes. Among BRCA1 carriers, pregnancy after breast cancer was associated with lower rates of disease recurrence. Among BRCA2 carriers, however, pregnancy was linked to a possible increase in recurrence risk, with an adjusted hazard ratio of 1.55. This doesn’t mean BRCA2 carriers can’t have children after breast cancer, but it does mean the conversation with an oncologist should be more nuanced.
Breastfeeding After Breast Cancer Treatment
Breastfeeding is possible after breast cancer surgery and radiation, though the treated breast will likely produce little to no milk. In a recent survey of women who had lumpectomy followed by radiation, 11 out of 12 attempted breastfeeding, and all were able to breastfeed to some degree. However, every one of them relied on the untreated breast as the primary milk source. Only 3 out of 11 were able to exclusively breastfeed without formula supplementation.
The irradiated breast showed minimal activity after delivery: only a few women experienced any colostrum, milk leakage, or engorgement on that side. Among those who breastfed, duration ranged widely, from 2 months to over a year. The most common reason for stopping was insufficient milk supply, followed by the emotional and physical toll of breastfeeding, and in some cases, the need to restart cancer medications that are unsafe during lactation.
Metastatic Breast Cancer and Pregnancy
Pregnancy in the setting of stage IV or metastatic breast cancer is a fundamentally different situation. Data on this scenario are extremely limited, and there are no standardized guidelines. The medical literature consists mostly of individual case reports rather than large studies. For HER2-positive metastatic disease, key treatments like trastuzumab must be stopped during pregnancy, leaving fewer therapeutic options to control the cancer. The combination of active metastatic disease, pregnancy, and young age are all considered negative prognostic factors. Any decision to pursue pregnancy with metastatic breast cancer requires careful, individualized discussion with an oncology team about the tradeoffs involved.